マラリア・ワクチンの世界市場

マラリア・ワクチンの世界市場は2030年までに72億米ドルに達する

2024年に24億米ドルと推定されるマラリア・ワクチンの世界市場は、2024年から2030年にかけてCAGR 20.0％で成長し、2030年には72億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプレ赤血球ワクチンは、CAGR 20.9%を記録し、分析期間終了時には41億米ドルに達すると予測されます。赤血球ワクチン分野の成長率は分析期間中CAGR 20.7%と推定されます。

米国市場は6億5,530万米ドルと推定、中国はCAGR26.4％で成長予測

米国のマラリア・ワクチン市場は、2024年に6億5,530万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは26.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ14.8％と18.2％と予測されています。欧州では、ドイツがCAGR約16.0%で成長すると予測されています。

世界のマラリア・ワクチン市場- 主要動向と促進要因のまとめ

なぜマラリア・ワクチンは世界の公衆衛生における重要なマイルストーンなのか？

マラリア・ワクチンは、世界で最も永続的で致命的な感染症との闘いにおいて、画期的な進歩を遂げました。マラリアは毎年何十万人もの命を奪っており、その多くはサハラ以南のアフリカで、子どもたちの間で不釣り合いに発生しています。効果的な予防接種は、世界のマラリア対策における「ミッシング・リンク」と長い間考えられてきました。蚊の駆除、抗マラリア薬、迅速診断ツールは大きな進歩を遂げたが、ワクチンは長期的な予防効果をもたらし、感染を減らし、既存の対策を補完する可能性を秘めています。

RTS,S/AS01（モスキリックス）ワクチンに続き、R21/Matrix-Mワクチンが導入されたことは、マラリア対策が消極的なものから積極的な予防へと歴史的な転換を遂げたことを意味します。これらのワクチンは、最も致死率の高いマラリア原虫を標的として設計されています。世界保健機関との提携や官民パートナーシップにより、資源が限られた環境での利用が加速しています。マラリア撲滅目標を達成するために、医療制度が拡張可能で費用対効果の高い手段を求める中、ワクチンをベースとした解決策を支持する機運が高まっています。

調査、資金調達、展開戦略はどのように進化しているのか？

マラリアワクチンの状況は、公共投資や慈善事業への投資の急増、バイオテクノロジー企業の関与の増加、WHO、Gavi、ユニセフなどの世界的組織からの支援により、急速に進化しています。次世代ワクチンの臨床試験は拡大しており、より広範な寄生虫株と、より長持ちする免疫をターゲットにしています。ナノ粒子をベースとした製剤やmRNAアプローチなど、ワクチン送達プラットフォームの革新が、有効性やロジスティクスの制約を克服するために検討されています。

同時に、ガーナ、ケニア、マラウイといった国々での協調的な展開が、将来の配布モデルに情報を与えています。予防接種の普及には、定期的な予防接種プログラムとの統合が不可欠であり、医療システムは、コールドチェーン、トレーニング、コミュニティ参加のためのインフラを構築しています。これと並行して、ワクチンの在庫管理、接種率のモニタリング、副作用の追跡のために、需要予測ツールやデジタルヘルスレジストリーが採用されています。このようなエコシステム・レベルの取り組みは、科学的進歩を測定可能な公衆衛生の成果に結びつけるために不可欠です。

最も恩恵を受ける地域と人口は？

サハラ以南のアフリカは、依然として世界のマラリア罹患の震源地であり、年間患者数と死亡者数の90％以上を占めています。5歳未満の子どもと妊婦は最も脆弱な集団であり、これらの人々を対象としたワクチン接種プログラムにより、罹患率と死亡率を大幅に減らすことができます。南アジア、オセアニア、中南米の一部を含む広範な熱帯地域も、気候変動によって蚊の生息地が拡大し、感染の動態が変化するため、マラリア・ワクチンの恩恵を受けることになります。

難民キャンプ、紛争地域、遠隔地の農村地域は、伝統的な予防法の維持が困難であるため、マラリア対策として特にワクチンに依存しています。都市の拡大や媒介蚊の行動の変化も疫学的状況を変化させており、保健当局はリスクプロファイルを再評価し、新たなホットスポットにワクチンを配備する必要に迫られています。ワクチンへのアクセスを国のマラリア対策戦略やドナーの支援と整合させることは、公平性と効果を確保する上で極めて重要です。

マラリア・ワクチン市場の成長はいくつかの要因によってもたらされる...

マラリア・ワクチン市場の開拓は、流行地域における疾病負担の増加、国際保健機関からの資金援助拡大、ワクチン開発パイプラインの加速化など、いくつかの要因によって推進されています。現在のワクチンの安全性と部分的な有効性が実証されたことで、早期導入と国家予防接種スケジュールへの組み入れが進んでいます。政府調達、ドナーからの補助金、官民協力により、アフリカ全土、そして世界各地への迅速な配備が促進されています。

抗原設計、アジュバント技術、送達システムの進歩により、ワクチン・ポートフォリオが拡大し、免疫耐久性が向上しています。気候に関連したマラリア伝播の変化により、より広範な地理的展開の必要性が高まる一方、都市化と人の移動の増加により、スケーラブルで予防的な介入の緊急性が高まっています。マラリア・ワクチン接種キャンペーンの成功は、さらなる技術革新と投資を促進し、長期的な撲滅活動への強固な基盤を確立すると期待されています。

セグメント

タイプ（前赤血球型、赤血球型、マルチ抗原型、その他のタイプ）、薬剤タイプ（マラリア原虫、ビバックス原虫、アノフェレス種）、エンドユーザー（病院、専門クリニック、在宅医療、その他のエンドユーザー）

調査対象企業の例（注目の合計32社）

• AdvaCare Pharma
• Ajanta Pharma Ltd.
• Amneal Pharmaceuticals LLC
• Bharat Biotech
• Bliss GVS Pharma Ltd.
• CellFree Sciences Co., Ltd.
• GenVec Inc.
• GeoVax Labs Inc.
• GlaxoSmithKline plc（GSK）
• Hikma Pharmaceuticals PLC
• Inovio Pharmaceuticals
• Ipca Laboratories Ltd.
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Sanaria Inc.
• Serum Institute of India Pvt. Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Malaria Vaccines Market to Reach US$7.2 Billion by 2030

The global market for Malaria Vaccines estimated at US$2.4 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Pre-Erythrocytic Vaccines, one of the segments analyzed in the report, is expected to record a 20.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Erythrocytic Vaccines segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$655.3 Million While China is Forecast to Grow at 26.4% CAGR

The Malaria Vaccines market in the U.S. is estimated at US$655.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 26.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.8% and 18.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.0% CAGR.

Global Malaria Vaccines Market - Key Trends & Drivers Summarized

Why Are Malaria Vaccines a Pivotal Milestone in Global Public Health?

Malaria vaccines represent a breakthrough in the fight against one of the world’s most persistent and deadly infectious diseases. With malaria claiming hundreds of thousands of lives annually-mostly in Sub-Saharan Africa and disproportionately among children-effective immunization has long been considered the “missing link” in global malaria control strategies. While mosquito control, antimalarial drugs, and rapid diagnostic tools have made significant progress, vaccines offer the potential to provide long-term protection, reduce transmission, and complement existing interventions.

The introduction of the RTS,S/AS01 (Mosquirix) vaccine, followed by the R21/Matrix-M vaccine, marks a historic shift from reactive malaria control to proactive prevention. These vaccines are designed to target the Plasmodium falciparum parasite, the most deadly malaria strain. Their deployment in high-burden countries has already begun, with global health alliances and public-private partnerships accelerating access in resource-limited settings. The momentum behind vaccine-based solutions is building as health systems seek scalable, cost-effective tools to achieve elimination targets.

How Are Research, Funding, and Deployment Strategies Evolving?

The malaria vaccine landscape is evolving rapidly, driven by a surge in public and philanthropic investment, increased engagement from biotech firms, and support from global organizations such as WHO, Gavi, and UNICEF. Clinical trials for next-generation vaccines are expanding, targeting broader parasite strains and longer-lasting immunity. Innovations in vaccine delivery platforms-such as nanoparticle-based formulations and mRNA approaches-are being explored to overcome efficacy and logistics limitations.

Simultaneously, coordinated rollouts in countries like Ghana, Kenya, and Malawi are informing future distribution models. Integration with routine immunization programs is critical to achieving widespread coverage, and health systems are building infrastructure for cold chain, training, and community engagement. In parallel, demand forecasting tools and digital health registries are being employed to manage vaccine inventories, monitor coverage, and track side effects. These ecosystem-level efforts are critical to turning scientific advances into measurable public health outcomes.

Which Regions and Populations Stand to Benefit the Most?

Sub-Saharan Africa remains the epicenter of global malaria incidence, accounting for over 90% of cases and deaths annually. Children under five and pregnant women are the most vulnerable groups, and vaccination programs targeting these populations can significantly reduce morbidity and mortality. The broader tropical belt, including parts of South Asia, Oceania, and Central America, also stands to benefit from malaria vaccines as climate change expands mosquito habitats and alters transmission dynamics.

Refugee camps, conflict zones, and remote rural communities-where traditional prevention methods are difficult to sustain-are particularly reliant on vaccines for malaria control. Urban expansion and changes in vector behavior are also shifting the epidemiological landscape, prompting health authorities to reassess risk profiles and deploy vaccines in emerging hotspots. The alignment of vaccine access with national malaria control strategies and donor support is crucial to ensuring equity and impact.

The Growth in the Malaria Vaccines Market Is Driven by Several Factors…

The growth in the malaria vaccines market is driven by several factors including increasing disease burden in endemic regions, expanded funding from international health organizations, and accelerated vaccine development pipelines. The demonstrated safety and partial efficacy of current vaccines are supporting early adoption and inclusion in national immunization schedules. Government procurement, donor subsidies, and public-private collaboration are facilitating rapid deployment across Africa and beyond.

Advancements in antigen design, adjuvant technology, and delivery systems are expanding the vaccine portfolio and improving immune durability. Climate-related shifts in malaria transmission are pushing the need for broader geographic deployment, while growing urbanization and human mobility are increasing the urgency for scalable and preventive interventions. The success of malaria vaccination campaigns is expected to drive further innovation and investment, establishing a strong foundation for long-term eradication efforts.

SCOPE OF STUDY:

The report analyzes the Malaria Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Pre-Erythrocytic, Erythrocytic, Multi-Antigen, Other Types); Agent Type (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species); End-Use (Hospitals, Specialty Clinics, Homecare, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AdvaCare Pharma
• Ajanta Pharma Ltd.
• Amneal Pharmaceuticals LLC
• Bharat Biotech
• Bliss GVS Pharma Ltd.
• CellFree Sciences Co., Ltd.
• GenVec Inc.
• GeoVax Labs Inc.
• GlaxoSmithKline plc (GSK)
• Hikma Pharmaceuticals PLC
• Inovio Pharmaceuticals
• Ipca Laboratories Ltd.
• Johnson & Johnson
• Lupin Limited
• Merck & Co., Inc.
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Sanaria Inc.
• Serum Institute of India Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Malaria Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Global Burden of Malaria in Sub-Saharan Africa Drives Urgency for Effective Vaccine Development and Deployment
  • WHO Prequalification of RTS,S/AS01 and Other Leading Candidates Strengthens Confidence in Malaria Vaccine Programs
  • Rising Funding From Gavi, CEPI, and Global Health Alliances Supports Procurement and Rollout of Malaria Vaccines
  • Expansion of Pediatric Immunization Campaigns in High-Risk Areas Facilitates Integration of Malaria Vaccines Into National Schedules
  • Breakthroughs in mRNA and Recombinant Protein Platforms Accelerate Innovation in Next-Gen Malaria Vaccine Candidates
  • Rising Use of Vaccine Efficacy Modeling and Genomic Surveillance Supports Targeted Immunization Strategies
  • Push for Seasonal Malaria Vaccine Campaigns in Endemic Zones Enhances Use in Combination With Chemoprevention
  • Increased Global Health Security Emphasis Drives Vaccine Equity and Manufacturing Scale-Up for Malaria Prevention
  • Emergence of Multi-Strain and Multi-Stage Vaccine Candidates Strengthens Long-Term Protection Potential
  • Integration of Malaria Vaccines With Maternal and Infant Health Programs Expands Reach in Rural and Underserved Regions
  • Use of Cold Chain Logistics and Vial-Level Traceability Enhances Efficiency of Malaria Vaccine Distribution
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Malaria Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Malaria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pre-Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pre-Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Pre-Erythrocytic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Erythrocytic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Multi-Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Multi-Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Multi-Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Homecare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Homecare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Homecare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Plasmodium Falciparum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Plasmodium Falciparum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Plasmodium Falciparum by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Plasmodium Vivax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Plasmodium Vivax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Plasmodium Vivax by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Anopheles Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Anopheles Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Anopheles Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• JAPAN
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• CHINA
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• EUROPE
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Malaria Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• FRANCE
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• GERMANY
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Malaria Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• INDIA
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Malaria Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Malaria Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
• AFRICA
  • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030

IV. COMPETITION